Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer

Kenji Tamura, Isamu Okamoto, Tomohiro Ozaki, Tatsuhiko Kashii, Koji Takeda, Masashi Kobayashi, Kaoru Matsui, Takashi Shibata, Takayasu Kurata, Kazuhiko Nakagawa, Masahiro Fukuoka

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The objective of this phase I/II study was to determine the recommended dose (RD) of S-1 and carboplatin (CBDCA), and to evaluate the efficacy and safety of this combination in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Chemotherapy-naïve patients were treated with S-1 given orally on days 1-14, and CBDCA infused intravenously on day 1, repeated every 3 weeks. RD was AUC5 of CBDCA and 80 mg/m2 of S-1. Nineteen patients were treated at the RD. The overall response was 30.8% (95% confidence interval: 17.1-58.3%). The response rate in the RD was 36.8% (95% CI: 16.3-61.6%). The median overall survival time was 11.1 months (95% CI: 8.1-15.3 months) and the median progression-free survival time was 5.0 months (95% CI: 3.6-6.0 months). Major grades 3-4 toxicities were thrombocytopaenia (47%), anaemia (26%) and infection (16%). This is the first report to show promising activity of this combination in phase II, including survival data and manageable toxicity, especially in outpatients receiving treatment for advanced NSCLC.

Original languageEnglish
Pages (from-to)2132-2137
Number of pages6
JournalEuropean Journal of Cancer
Volume45
Issue number12
DOIs
Publication statusPublished - Aug 1 2009

Fingerprint

Carboplatin
Non-Small Cell Lung Carcinoma
Survival
Disease-Free Survival
Anemia
Outpatients
Confidence Intervals
Safety
Drug Therapy
Therapeutics
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. / Tamura, Kenji; Okamoto, Isamu; Ozaki, Tomohiro; Kashii, Tatsuhiko; Takeda, Koji; Kobayashi, Masashi; Matsui, Kaoru; Shibata, Takashi; Kurata, Takayasu; Nakagawa, Kazuhiko; Fukuoka, Masahiro.

In: European Journal of Cancer, Vol. 45, No. 12, 01.08.2009, p. 2132-2137.

Research output: Contribution to journalArticle

Tamura, K, Okamoto, I, Ozaki, T, Kashii, T, Takeda, K, Kobayashi, M, Matsui, K, Shibata, T, Kurata, T, Nakagawa, K & Fukuoka, M 2009, 'Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer', European Journal of Cancer, vol. 45, no. 12, pp. 2132-2137. https://doi.org/10.1016/j.ejca.2009.04.003
Tamura, Kenji ; Okamoto, Isamu ; Ozaki, Tomohiro ; Kashii, Tatsuhiko ; Takeda, Koji ; Kobayashi, Masashi ; Matsui, Kaoru ; Shibata, Takashi ; Kurata, Takayasu ; Nakagawa, Kazuhiko ; Fukuoka, Masahiro. / Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. In: European Journal of Cancer. 2009 ; Vol. 45, No. 12. pp. 2132-2137.
@article{c2c16134f6df4a74ac20cacca87b458c,
title = "Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer",
abstract = "The objective of this phase I/II study was to determine the recommended dose (RD) of S-1 and carboplatin (CBDCA), and to evaluate the efficacy and safety of this combination in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Chemotherapy-na{\"i}ve patients were treated with S-1 given orally on days 1-14, and CBDCA infused intravenously on day 1, repeated every 3 weeks. RD was AUC5 of CBDCA and 80 mg/m2 of S-1. Nineteen patients were treated at the RD. The overall response was 30.8{\%} (95{\%} confidence interval: 17.1-58.3{\%}). The response rate in the RD was 36.8{\%} (95{\%} CI: 16.3-61.6{\%}). The median overall survival time was 11.1 months (95{\%} CI: 8.1-15.3 months) and the median progression-free survival time was 5.0 months (95{\%} CI: 3.6-6.0 months). Major grades 3-4 toxicities were thrombocytopaenia (47{\%}), anaemia (26{\%}) and infection (16{\%}). This is the first report to show promising activity of this combination in phase II, including survival data and manageable toxicity, especially in outpatients receiving treatment for advanced NSCLC.",
author = "Kenji Tamura and Isamu Okamoto and Tomohiro Ozaki and Tatsuhiko Kashii and Koji Takeda and Masashi Kobayashi and Kaoru Matsui and Takashi Shibata and Takayasu Kurata and Kazuhiko Nakagawa and Masahiro Fukuoka",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.ejca.2009.04.003",
language = "English",
volume = "45",
pages = "2132--2137",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer

AU - Tamura, Kenji

AU - Okamoto, Isamu

AU - Ozaki, Tomohiro

AU - Kashii, Tatsuhiko

AU - Takeda, Koji

AU - Kobayashi, Masashi

AU - Matsui, Kaoru

AU - Shibata, Takashi

AU - Kurata, Takayasu

AU - Nakagawa, Kazuhiko

AU - Fukuoka, Masahiro

PY - 2009/8/1

Y1 - 2009/8/1

N2 - The objective of this phase I/II study was to determine the recommended dose (RD) of S-1 and carboplatin (CBDCA), and to evaluate the efficacy and safety of this combination in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Chemotherapy-naïve patients were treated with S-1 given orally on days 1-14, and CBDCA infused intravenously on day 1, repeated every 3 weeks. RD was AUC5 of CBDCA and 80 mg/m2 of S-1. Nineteen patients were treated at the RD. The overall response was 30.8% (95% confidence interval: 17.1-58.3%). The response rate in the RD was 36.8% (95% CI: 16.3-61.6%). The median overall survival time was 11.1 months (95% CI: 8.1-15.3 months) and the median progression-free survival time was 5.0 months (95% CI: 3.6-6.0 months). Major grades 3-4 toxicities were thrombocytopaenia (47%), anaemia (26%) and infection (16%). This is the first report to show promising activity of this combination in phase II, including survival data and manageable toxicity, especially in outpatients receiving treatment for advanced NSCLC.

AB - The objective of this phase I/II study was to determine the recommended dose (RD) of S-1 and carboplatin (CBDCA), and to evaluate the efficacy and safety of this combination in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Chemotherapy-naïve patients were treated with S-1 given orally on days 1-14, and CBDCA infused intravenously on day 1, repeated every 3 weeks. RD was AUC5 of CBDCA and 80 mg/m2 of S-1. Nineteen patients were treated at the RD. The overall response was 30.8% (95% confidence interval: 17.1-58.3%). The response rate in the RD was 36.8% (95% CI: 16.3-61.6%). The median overall survival time was 11.1 months (95% CI: 8.1-15.3 months) and the median progression-free survival time was 5.0 months (95% CI: 3.6-6.0 months). Major grades 3-4 toxicities were thrombocytopaenia (47%), anaemia (26%) and infection (16%). This is the first report to show promising activity of this combination in phase II, including survival data and manageable toxicity, especially in outpatients receiving treatment for advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=67650935590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650935590&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2009.04.003

DO - 10.1016/j.ejca.2009.04.003

M3 - Article

C2 - 19409773

AN - SCOPUS:67650935590

VL - 45

SP - 2132

EP - 2137

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0959-8049

IS - 12

ER -